Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Halozyme Therapeutics
HALO
5
eBay
EBAY
US Stock MarketDetailed Quotes
ABCL AbCellera Biologics
- 2.310
- +0.240+11.59%
Trading Apr 11 14:30 ET
688.35MMarket Cap-4.20P/E (TTM)
2.350High2.080Low3.82MVolume2.140Open2.070Pre Close8.58MTurnover1.88%Turnover RatioLossP/E (Static)297.99MShares4.34052wk High0.65P/B468.47MFloat Cap1.89152wk Low--Dividend TTM202.80MShs Float71.910Historical High--Div YieldTTM13.04%Amplitude1.891Historical Low2.250Avg Price1Lot Size
AbCellera Biologics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -147.41%-108.56M | 59.21%-8M | -27,147.17%-28.88M | -250.56%-29.97M | 5.34%-41.71M | -115.82%-43.88M | -163.44%-19.61M | 99.92%-106K | -92.71%19.9M | -143.97%-44.06M |
| Net income from continuing operations | -11.24%-162.86M | 27.44%-34.21M | -78.63%-51.11M | -20.97%-36.93M | -1.25%-40.61M | -192.35%-146.4M | -57.73%-47.15M | -207.46%-28.61M | -349.93%-30.53M | -123.79%-40.11M |
| Depreciation and amortization | 213.97%97M | 52.60%13.9M | 416.87%38.3M | 424.21%38.04M | -4.97%6.77M | -6.67%30.89M | -40.70%9.11M | 10.12%7.41M | 20.11%7.26M | 43.17%7.12M |
| Other non cash items | -1,360.56%-84.44M | ---35.71M | ---9.61M | -5,034.59%-40.82M | 146.97%1.71M | -189.86%-5.78M | ---- | ---- | -370.41%-795K | -513.85%-3.63M |
| Change In working capital | -295.41%-25.84M | 957.56%14.9M | -180.04%-5.73M | -129.14%-8.04M | -17.75%-26.98M | -55.66%13.23M | -95.14%1.41M | 104.08%7.16M | -89.45%27.57M | 73.05%-22.91M |
| -Change in receivables | -104.91%-75.12M | -99.86%-20.86M | -76.79%-19.82M | 50.73%-15.86M | -208.16%-18.58M | -134.44%-36.66M | -115.78%-10.44M | 81.10%-11.21M | -111.65%-32.18M | 109.72%17.18M |
| -Change in payables and accrued expense | 170.41%10.64M | 159.67%15.33M | -79.46%1.39M | -94.86%1.98M | 76.74%-8.06M | -621.30%-15.1M | -166.41%-25.68M | 105.69%6.78M | 353.71%38.45M | -137.02%-34.65M |
| -Change in other current assets | -33.70%5.95M | 6.11%4.95M | -72.89%2.48M | 73.33%2.13M | 40.54%-3.61M | 753.09%8.98M | 3,228.19%4.66M | 214.18%9.15M | -64.01%1.23M | 19.77%-6.06M |
| -Change in other working capital | -41.64%32.69M | -52.87%15.49M | 318.42%10.22M | -81.50%3.71M | 425.97%3.26M | 176.55%56.01M | 143.42%32.87M | 2,141.28%2.44M | 728.16%20.08M | -88.97%620K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -147.41%-108.56M | 59.21%-8M | -27,147.17%-28.88M | -250.56%-29.97M | 5.34%-41.71M | -115.82%-43.88M | -163.44%-19.61M | 99.92%-106K | -92.71%19.9M | -143.97%-44.06M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 154.91%121.41M | 246.79%35.7M | 128.92%3.7M | 251.49%52.1M | 119.99%29.91M | 37.30%-221.11M | -42.55%-24.32M | 95.47%-12.79M | -26.45%-34.39M | -467.32%-149.61M |
| Net PPE purchase and sale | -1.88%-78.4M | -8.31%-15.63M | 8.93%-18.52M | 26.07%-20.11M | -61.11%-24.14M | -8.90%-76.95M | -17.04%-14.43M | -62.48%-20.33M | 13.16%-27.2M | -3.37%-14.98M |
| Net intangibles purchase and sale | --0 | ---- | ---- | ---- | ---- | 72.00%-560K | ---- | ---- | ---- | ---- |
| Net business purchase and sale | -43.36%-19.63M | 51.96%-1.67M | -101.52%-7.14M | -122.91%-4.91M | -32.18%-5.91M | 46.69%-13.69M | 41.17%-3.48M | 13.13%-3.54M | 70.05%-2.2M | 46.38%-4.47M |
| Net investment purchase and sale | 218.36%183.72M | 387.69%46.45M | 431.15%19.95M | 746.36%64.54M | 139.74%52.79M | 42.66%-155.22M | -1,294.13%-16.14M | 101.39%3.76M | -266.92%-9.99M | -2,064.72%-132.85M |
| Net other investing changes | 41.08%35.71M | -36.26%6.56M | 28.24%9.4M | 151.64%12.58M | 166.17%7.17M | 54.02%25.31M | 340.79%10.29M | 22.13%7.33M | -9.12%5M | 3.74%2.69M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 154.91%121.41M | 246.79%35.7M | 128.92%3.7M | 251.49%52.1M | 119.99%29.91M | 37.30%-221.11M | -42.55%-24.32M | 95.47%-12.79M | -26.45%-34.39M | -467.32%-149.61M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 23.30%12.77M | 10.01%4.14M | -52.56%3.15M | 532.70%2.65M | 718.12%2.83M | 736.12%10.36M | 978.80%3.77M | 34,994.74%6.63M | -64.28%419K | 85.37%-458K |
| Proceeds from stock option exercised by employees | ---- | ---- | -11.33%227K | 38.02%461K | 82.04%892K | ---- | ---- | --256K | --334K | --490K |
| Net other financing activities | 23.30%12.77M | 18.10%5.72M | -54.22%2.92M | 2,476.47%2.19M | 304.54%1.94M | 736.12%10.36M | 75.86%4.85M | 2,649.60%6.37M | -90.95%85K | 81.31%-948K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 23.30%12.77M | 10.01%4.14M | -52.56%3.15M | 532.70%2.65M | 718.12%2.83M | 736.12%10.36M | 978.80%3.77M | 34,994.74%6.63M | -64.28%419K | 85.37%-458K |
| Net cash flow | ||||||||||
| Beginning cash position | -61.27%160.61M | -22.92%153.93M | -15.18%175.6M | -31.52%150.86M | -61.27%160.61M | -17.26%414.65M | -50.08%199.71M | -74.67%207.04M | -61.46%220.31M | -17.26%414.65M |
| Current changes in cash | 110.06%25.62M | 179.28%31.85M | -251.95%-22.04M | 276.17%24.78M | 95.38%-8.97M | -231.15%-254.63M | -382.92%-40.17M | 98.47%-6.26M | -105.70%-14.07M | -374.52%-194.13M |
| Effect of exchange rate changes | -544.31%-2.62M | -302.25%-2.16M | 134.52%367K | -105.40%-43K | -266.67%-781K | 106.14%589K | 193.41%1.07M | 87.57%-1.06M | 166.03%797K | -4.41%-213K |
| End cash Position | 14.32%183.62M | 14.32%183.62M | -22.92%153.93M | -15.18%175.6M | -31.52%150.86M | -61.27%160.61M | -61.27%160.61M | -50.08%199.71M | -74.67%207.04M | -61.46%220.31M |
| Free cash flow | -54.02%-186.95M | 31.71%-23.63M | -131.92%-47.4M | -586.16%-50.08M | -11.52%-65.85M | -159.30%-121.38M | -286.21%-34.6M | 85.54%-20.44M | -103.02%-7.3M | -168.88%-59.05M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
